Vall d’Hebron Institute of Oncology (VHIO)

A Severo Ochoa center since 2021

The Vall d’Hebron Institute of Oncology (VHIO) is a reference center for personalized medicine in oncologycreated in 2006.

Thanks to its pioneering model of multidisciplinary and translational researchand its participation in consortia and projects with other prestigious centers around the world, it has positioned itself as one of the most important comprehensive centers in Europe capable of transforming, in record time, the latest research discoveries in the laboratory in early clinical trials and, therefore, in new opportunities for patients.

Our team is made up of more than 450 people, including preclinical and clinical researchers, oncologists, nursing staff and research support professionals, distributed between the VHIO and the Vall d’Hebron University Hospital who are working in a coordinated way to find effective new treatments for patients. In this sense, more than 30% of all cancer patients at the Hospital are included in a clinical trial at VHIO, among 1,200 patients each year in clinical trials.

Since VHIO’s creation, it has contributed to 30 new drug indications and it’s participating or leading more than 20 international projects. Last year, our investigators published more than 450 articles with an average impact factor of 13,66. During VHIO’s life until December 31st,  2022, 28 patents and 4 spin-offs have been generated.

The Severo Ochoa Accreditation is particularly relevant because it reinforces VHIO translational approach to cancer research, covering all relevant stages of Precision Oncology, and making feasible the implementation of research advances into a clinical environment. It also legitimates the value of having an independent monographic cancer center into a Vall d’Hebron Hospital Campus.
Josep Tabernero
Director at VHIO